The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
 
Masatoshi Kudo
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Masafumi Ikeda
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD; MSD; MSD; MSD; Mylan; Mylan; Mylan; Mylan; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Consulting or Advisory Role - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Micron; Micron; Micron; Micron; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Shire; Shire; Shire; Shire; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Kenta Motomura
Honoraria - Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; AstraZeneca Japan; AstraZeneca Japan; AstraZeneca Japan; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Fujifilm; Fujifilm; Fujifilm; Fujifilm; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Shire; Shire; Shire; Shire; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; AstraZeneca Japan; AstraZeneca Japan; AstraZeneca Japan; Baxter; Baxter; Baxter; Baxter; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Naoya Kato
Speakers' Bureau - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD K.K; MSD K.K; MSD K.K; MSD K.K
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai
 
Corina E. Dutcus
Employment - Eisai; Eisai; Eisai; Eisai
 
Takashi Hisai
Employment - Eisai; Eisai; Eisai; Eisai
 
Mayumi Suzuki
Employment - Eisai; Eisai; Eisai; Eisai
 
Hiroki Ikezawa
Employment - Eisai; Eisai; Eisai; Eisai
 
Takeyuki Iwata
Employment - Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Stock and Other Ownership Interests - Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
 
Hiromitsu Kumada
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; MSD; MSD; MSD; MSD; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group
 
Masahiro Kobayashi
Speakers' Bureau - Eisai; Eisai; Eisai; Eisai